Go offline with the Player FM app!
Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D.
Manage episode 503716567 series 2739469
We love to hear from our listeners. Send us a message.
On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D. (00:00:00)
2. Introduction to Atul Deshpande (00:00:07)
3. From Academia to Industry (00:01:48)
4. Learning in Emerging Markets (00:04:18)
5. The Dupixent Launch Experience (00:09:30)
6. The GIK Mechanism of Action (00:16:05)
7. The IMMEDIATE-1 Trial Results (00:22:50)
8. Intellectual Property Strategy (00:33:44)
9. Expanding Beyond Heart Attacks (00:53:22)
10. Closing and Future Plans (01:01:08)
272 episodes
Manage episode 503716567 series 2739469
We love to hear from our listeners. Send us a message.
On this week's episode, Atul Deshpande, Ph.D., CEO at Immediate Therapeutics, talks about partnering with American cities to conduct clinical trials during ambulance rides to the hospital, with the goal of preserving heart function and reducing mortality related to acute cardiovascular events, including heart attacks. Deshpande reflects on his previous experience developing and commercializing Dupixent at Sanofi, describes the history and mechanism of Immediate's glucose-insulin-potassium (GIK) candidate, IMT-358, and explains why there is more to intellectual property than just patents.
Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.
Subscribe to our monthly Business of Biotech newsletter.
Get in touch with guest and topic suggestions: [email protected]
Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/
Chapters
1. Improving Cardiovascular Outcomes With Immediate Therapeutics' Atul Deshpande, Ph.D. (00:00:00)
2. Introduction to Atul Deshpande (00:00:07)
3. From Academia to Industry (00:01:48)
4. Learning in Emerging Markets (00:04:18)
5. The Dupixent Launch Experience (00:09:30)
6. The GIK Mechanism of Action (00:16:05)
7. The IMMEDIATE-1 Trial Results (00:22:50)
8. Intellectual Property Strategy (00:33:44)
9. Expanding Beyond Heart Attacks (00:53:22)
10. Closing and Future Plans (01:01:08)
272 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.